반응식
[NH:1]1[CH2:6][CH2:5][CH:4]([N:7]2[C:15]3[C:10](=[N:11][CH:12]=[CH:13][CH:14]=3)[NH:9][C:8]2=[O:16])[CH2:3][CH2:2]1.Cl[C:18]1[CH:23]=[C:22]([O:24][CH3:25])[N:21]=[C:20]([C:26]([N:28]2[C:36]3[C:31](=[CH:32][C:33]([F:37])=[CH:34][CH:35]=3)[CH2:30][CH2:29]2)=[O:27])[CH:19]=1>CN1C(=O)CCC1>[F:37][C:33]1[CH:32]=[C:31]2[C:36](=[CH:35][CH:34]=1)[N:28]([C:26]([C:20]1[N:21]=[C:22]([O:24][CH3:25])[CH:23]=[C:18]([N:1]3[CH2:2][CH2:3][CH:4]([N:7]4[C:15]5[C:10](=[N:11][CH:12]=[CH:13][CH:14]=5)[NH:9][C:8]4=[O:16])[CH2:5][CH2:6]3)[CH:19]=1)=[O:27])[CH2:29][CH2:30]2참가 물질
4
실험 절차
436 mg (2.00 mmol) 1-Piperidin-4-yl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one and 200 mg (0.652 mmol) of (4-chloro-6-methoxy-pyridin-2-yl)-(5-fluoro-2,3-dihydro-indol-1-yl)-methanone in 2 mL NMP were stirred overnight at 120° C. The reaction mixture was purified by preparative HPLC. The product-containing fractions were combined and evaporated down using the rotary evaporator.
후처리
- customThe reaction mixture was purified by preparative HPLC
- customevaporated
- customthe rotary evaporator
출처 및 근거
- ORD 기록
- ord-1ed47c91d9714f61b2d3f3551fcc692d
- 출처 데이터셋
- uspto-grants-2012_10
- 특허 번호
- US08278336B2
연결된 노트
불러오는 중…